Qorvo® Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing at the Point of Care
Retrieved on:
Thursday, August 4, 2022
PCR, POC, Detection limit, National Institute of Biomedical Imaging and Bioengineering, Diagnosis, Lod, Department, COVID-19, LOD, United States Department of Health and Human Services, Human services, Virus, Emergency Use Authorization, BAW, Federal, Point of care, Food, NIH, Biological engineering, National, Protein, COVID-19 contracts in the United Kingdom, OTC, FDA, Viral load, Act, QRVO, Limit, Technology, Clinical Laboratory, Health, Workflow, PPA, National Institute, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Solution, GLOBE, National Institutes of Health, CEO, COVID, LLC, Medical imaging, EVS, EUA, CLIA, Laboratory, Pharmaceutical industry, Vaccine, Medical device, Qorvo, Severe acute respiratory syndrome coronavirus 2, Omicron, Omnia
The FDA previously granted an EUA for use in moderate and high complexity settings such as laboratories.
Key Points:
- The FDA previously granted an EUA for use in moderate and high complexity settings such as laboratories.
- This EUA significantly expands the market for Qorvo beyond laboratories to include physician offices, urgent care centers, retail pharmacies, employee health testing, and any other locations where CLIA waived tests can be performed.
- The Qorvo Omnia platform provides a unique combination of performance, automated workflow and scalability to serve on-site testing needs in a very efficient manner."
- Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries.